Please login to the form below

Not currently logged in
Email:
Password:

HER2 inhibitor

This page shows the latest HER2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Seattle Genetics wins FDA priority review for oral HER2 drug

Seattle Genetics wins FDA priority review for oral HER2 drug

If approved will compete with AZ/Daiichi Sankyo's Enhertu. Seattle Genetics has scored a US Food and Drug Administration (FDA) priority review for its oral HER2 inhibitor tucatinib in breast ... If Seattle does gain approval for tucatinib, it will go on

Latest news

  • AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

    The US regulator has cleared the HER2 inhibitor drug – now known as Enhertu (trastuzumab deruxtecan) – for metastatic HER2-positive disease in patients who have previously been treated with two or more ... s chemotherapy Xeloda (capecitabine) in

  • AZ, Daiichi Sankyo strengthen case for HER2 candidate AZ, Daiichi Sankyo strengthen case for HER2 candidate

    Kadcyla is the smallest in terms of sales in Roche’s HER2 franchise, with its sales falling behind those of Herceptin (trastuzumab) and Perjeta (pertuzumab). ... Also looking to encroach on the HER2 market is Seattle Genetics, with its orally-active

  • Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

    It’s due for first regulatory verdicts in 2021. Pevonedistat (TAK-924) for HR-MDS: Pevonedistat is a selective NEDD8 activating enzyme (NAE) inhibitor being developed as a cancer treatment, initially ... TAK-788 for non-small cell lung cancer:Phase 1/2

  • Seattle Genetics preps filing next year for oral HER2 drug Seattle Genetics preps filing next year for oral HER2 drug

    Company has positive phase 3 data to support filings. Seattle Genetics has positive phase 3 data in hand for its orally-active HER2 inhibitor tucatinib in breast cancer that the company ... on the massive success of Roche’s HER2 franchise, which

  • AZ’s bet on Daiichi’s rival to Kadcyla pays off AZ’s bet on Daiichi’s rival to Kadcyla pays off

    patients with refractory HER2-positive breast cancer who continue to have high unmet medical need,” he added. ... DS-8201 is said to be a more potent ADC than Roche’s drug because it pairs the anti-HER2 antibody with a topoisomerase inhibitor –

More from news
Approximately 2 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    440. OncoEthix / Merck &Co. Lead product oral BET inhibitor, OTX015 for oncology indications (p1b). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).

  • Pharma deals during April 2014 Pharma deals during April 2014

    GSK's recently approved MEK inhibitor Mekinist and BRAF inhibitor Tafinlar will position Novartis to become a leader in the potential blockbuster market for metastatic melanoma, neglected by their current portfolio. ... Additional GSK products include

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics